Fri, Sep 19, 2014, 10:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Thoratec Corp. Message Board

bigsmartsta 592 posts  |  Last Activity: 9 hours ago Member since: Apr 21, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bigsmartsta bigsmartsta 9 hours ago Flag

    METHODS AND RESULTS:

    Thirty-nine subjects with New York Heart Association class II to IV ischemic HF, ejection fraction between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be revascularized were enrolled in a prospective, nonrandomized, multicenter investigation testing percutaneous ventricular restoration using the Parachute device. The safety primary end point was defined as successful procedure without device-related major adverse cardiac events during 6 months. Clinical and echocardiographic outcomes were obtained at 6, 12, 24, and 36 months post-treatment. Echocardiographic and end point data were adjudicated independently. Of the 39 subjects enrolled, device implantation was attempted in 34 and successful in 31 patients. Twenty-three subjects reached 3 years post-treatment with the device implanted. New York Heart Association symptom class was improved or maintained in 85% of subjects. Left ventricle end-diastolic volume index and end-systolic volume index were reduced from 128.4±22.1 and 94.9±22.3 mL/m(2) preimplant to 115.2±23.1 and 87.3±18.7 mL/m(2) at 3-year follow-up (end-diastolic volume index, P=0.0056; end-systolic volume index, P=0.4719). The cumulative incidence of HF hospitalization or death was 16.1%, 32.3%, and 38.7% at 12, 24, and 36 months, respectively. By 3-year follow-up, 2 (6.5%) of 31 patients with successful implant had died from cardiac reasons, with no cardiac deaths occurring past 6 months post-treatment.

    CONCLUSIONS:

    The first series of ischemic HF patients treated with percutaneous ventricular restoration using the Parachute device demonstrates feasibility and safety of the device LESS THAN OR EQUAL 3 years post-treatment.

  • Circ Heart Fail. 2014 Sep;7(5):752-8. doi: 10.1161/CIRCHEARTFAILURE.114.001127. Epub 2014 Jul 18.

    Percutaneous Ventricular Restoration Using the Parachute Device in Patients With Ischemic Heart Failure: Three-Year Outcomes of the PARACHUTE First-in-Human Study.

    Costa MA1, Mazzaferri EL Jr2, Sievert H2, Abraham WT2.

    Author information

    1From the Center for Research and Innovation Harrington Heart and Vascular Institute University Hospitals, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH (M.A.C.); Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH (E.L.M., W.T.A.); CardioVascular Center, Frankfurt, Germany (H.S.). Marco.Costa@UHhospitals.org.
    2From the Center for Research and Innovation Harrington Heart and Vascular Institute University Hospitals, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH (M.A.C.); Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH (E.L.M., W.T.A.); CardioVascular Center, Frankfurt, Germany (H.S.).

    Abstract

    BACKGROUND:

    Left ventricle remodeling after anterior wall myocardial infarction leads to increased left ventricle volumes, myocardial stress, and ultimately heart failure (HF). Treatment options are limited for these high-risk HF patients. A study was conducted to assess safety and feasibility of a percutaneous ventricular restoration therapy using the Parachute device in subjects with HF because of a cardiac ischemic event.

  • EX1414 sounds like a broken record with his 30-hospitals committed.

    Does SSH have to wait another two years before committed becomes recruiting???

  • If the C-Pulse is the answer to HF for class 3 and Amb. Class 4, why did ONLY two hospitals join the rush to implant?? Especially if the data is outstanding?

  • What about you Jodi? You certainly made some intelligent post?

    Just simple arithmetic that can be easily understood and challenged.

  • A simple question that surely someone can explain to me.

  • Simple elementary arithmetic plus some easy to understand logic can easily change my mind if I'm not correct.

    So where are all the elementary school graduates on this board?

  • To review the problem:

    1- The SSH C-Pulse Feasibility Trial Ended on June 8, 2011 according to an SSH press release.

    2- September 15, 2014 represents 3-years and 99-days from the announcement in 1)

    3- ( 3 Times 365 ) + 99 = 1194-days ago since the enrollment was completed.

    4- To quote the 'Single Center Paper' given at the TCT Conference On Sept 15, 2014

    "Two patients REMAIN clinically stable ON DEVICE SUPPORT (1178 and 982-days),"

    5- But the MINIMUM ACTIVE support could ONLY BE 1194-days since that was when enrollment was completed. (read: simple arithmetic.)

    6- So BOTH numbers, 1178 and 982-days supplied by the C-Pulse TCT paper appear FALSE????

    7- Basically, if BOTH those ACTIVE patients were implanted on the LAST DAY of ENROLLMENT COMPLETION, they both would have been implanted 1194-days.

    8- So how could they BOTH be active and have only 1178 and 982-days on the C-Pulse? Especially only 982-days?????

  • I don't see any challenges to my questions regarding the two so-called C-Pulse survivors for 982 and 1178-days??? When enrollment completion ended 1195-days ago???

  • To review the problem:

    1- The Feasibility Trial Ended on June 8, 2011 according to an SSH press release.
    2- September 15, 2014 represents 3-years and 99-days from the announcement in 1)
    3- ( 3 Times 365 ) + 99 = 1194-days ago since the enrollment was completed.
    4- To quote the 'Single Center Paper' given at the TCT:

    "Two patients REMAIN clinically stable ON DEVICE SUPPORT (1178 and 982-days),"

    5- But the MINIMUM ACTIVE support could ONLY BE 1194-days on support. (read: simple arithmetic.)

    6- So BOTH numbers, 1178 and 982-days) supplied by the TCT paper appear FALSE???? Less

    7- Basically, if BOTH those ACTIVE patients were implanted on the LAST DAY of ENROLLMENT COMPLETION, they both would have been implanted 1194-days.

    8- So how could they BOTH be active and have only 1178 and 982-days? Especially only 982-days?????

  • bigsmartsta bigsmartsta Sep 16, 2014 6:48 PM Flag

    I guess elementary school arithmetic is beyond your comprehension.

  • Reply to

    Was FALSE DATA Supplied At TCT???

    by bigsmartsta Sep 16, 2014 4:23 PM
    bigsmartsta bigsmartsta Sep 16, 2014 6:11 PM Flag

    No one cares???

  • Reply to

    Was FALSE DATA Supplied At TCT???

    by bigsmartsta Sep 16, 2014 4:23 PM
    bigsmartsta bigsmartsta Sep 16, 2014 4:44 PM Flag

    Basically, if BOTH those ACTIVE patients were implanted on the LAST DAY of ENROLLMENT COMPLETION, they both would have been implanted 1194-days.

    So how could they BOTH be active and have only 1178 and 982-days? Especially only 982-days?????

  • 1- The Feasibility Trial Ended on June 8, 2011 according to an SSH press release.
    2- September 15, 2014 represents 3-years and 99-days from the announcement in 1)
    3- ( 3 Times 365 ) + 99 = 1194-days ago since the enrollment was completed.
    4- To quote the 'Single Center Paper' given at the TCT:

    "Two patients REMAIN clinically stable ON DEVICE SUPPORT (1178 and 982-days),"

    5- But the MINIMUM ACTIVE support could ONLY BE 1194-days on support. (read: simple arithmetic.)

    6- So BOTH numbers, 1178 and 982-days) supplied by the TCT paper appear FALSE????

  • Great News for MYDICAR delivery technology is that enormous ongoing research will definitely benefit MYDICAR therapy and eventually guarantee multiple therapies for each patient.

    Place the following in the search box

    Delivering genes and proteins for cellular imaging, genetic medicine and cancer therapy

    By loading any specific protein and nucleic acid into an icosahedral phage T4 capsid-based nanoparticle, the resulting cell delivery vehicle's ligands can bind to the surface of specific target tissues to deliver the protein/DNA cargo. (Icosahedral viral nanoparticles are evolutionary protein shells assembled in a hierarchical order that results in a stable protein layer and an inner space for accommodating nucleic acids and proteins; a capsid is the protein shell of a virus.) The technique has drug- and gene-delivery applications in human diseases, diagnostic and cellular imaging, and other medical areas. Recently, scientists at US Naval Research Laboratory, Washington, DC and University of Maryland at Baltimore packaged T4 nanoparticles in vivo with active cyclic recombination, or Cre, recombinase (a genetic recombination enzyme used to manipulate genome structure and control gene expression) and in vitro with fluorescent mCherry (a fluorescent protein used as a marker when tagged to molecules and cell components) expression plasmid DNA, and delivered these nanoparticles into cancer cells: When released into cells in the presence of both DNA and protein, the recombinase enhances mCherry expression by circularization (that is, changing the packaged linear DNA into a circular loop). The researchers state that this efficient and specific packaging into capsids and the unpackaging of both DNA and protein with release of the enzymatically altered protein/DNA complexes from the nanoparticles into cells have potential in numerous downstream applications such as genetic and cancer therapeutics.

  • There were more than a million shares short.

    This volume indicates that there is no problem for the SHORTs to cover.

  • On October 15, there can be 99-MYDICAR patients who have reached and exceeded one-year.

    Among that set exceeding one-year there will be 20-MYDICAR patients who reached or exceeded two years. Those patients will be in the two to two years three-months.

    Certainly enough data already exists for the FDA. Therefore, the BREAKTHROUGH THERAPY designation gains more significance each month toward February 15, 2015.

  • And break out the champagne???

  • According to the Cleveland Clinic, an EF BELOW 40% indicates problems.

    Over time, however, in either form of heart failure, the organs in the body do not receive enough oxygen and nutrients, and the body's wastes are removed slowly. Eventually, vital systems break down.

THOR
26.14-0.26(-0.98%)Sep 19 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT